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Abstract Claudin-2 is a trans-membrane protein—compo-
nent of tight junctions in epithelial cells. Elevated claudin-2
expression has been reported in colorectal cancer (CRC). The
aim of this study was to investigate the expression patterns of
claudin-2 in human CRC samples and analyze its association
with clinical characteristics and treatment outcome. TMAs of
primary tumors from two cohorts of metastatic CRC (mCRC)
were used. Claudin-2 IHC staining was evaluated in a semi-
quantitative manner in different regions and cell types.
Claudin-2 expression was also analyzed by immunofluores-
cence in primary cultures of human CRC cancer-associated
fibroblasts (CAFs). Initial analyses identified previously
unrecognized expression patterns of claudin-2 in CAFs of
human CRC. Claudin-2 expression in CAFs of the invasive
margin was associated with shorter progression-free survival.
Subgroup analyses demonstrated that the survival associations
occurred among cases that received 5-FU+oxaliplatin combi-
nation treatment, but not in patients receiving 5-FU
±irinotecan. The finding was validated by analyses of the in-
dependent cohort. In summary, previously unreported stromal
expression of claudin-2 in CAFs of human CRC was detected
together with significant association between high claudin-2
expression in CAFs and shorter survival in 5-FU+oxaliplatin-
treated mCRC patients.
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Introduction
Up to 25%of colorectal cancer (CRC) patients have synchronous
distant metastases at the time of diagnosis, and another 20–25%
develop metachronous metastases [4, 29]. Surgical resection of
the distant metastases, most often located to the liver, remains the
only curative treatment leading to 5-year survival varying from
25 to 74% [7, 9]. KRAS and BRAF mutations are independent
predictors for survival among patients who undergo liver metas-
tases resection [12, 26]. Medical treatment of metastatic CRC
(mCRC) includes combination chemotherapy with or without
addition of targeted agents blocking EGFR-receptor signaling
or angiogenesis. With the exception of RAS mutations, used as
a marker to identify patients not benefiting from EGFR inhibi-
tors, no biomarkers are clinically used for other pharmacological
treatments of mCRC.
Tight junctions (TJs) are themost apical cell–cell adhesions in
the epithelial cells. The claudin superfamily transmembrane pro-
teins, including claudin-2, are important components of TJs.
Under normal conditions, claudin-2 expression is associatedwith
Bleaky^ epithelia of proximal tubule and in Bowman’s capsule of
the nephron [14]. More recently, TJ proteins have been implied
in Bnoncanonical^ functions in epithelial and other cell types.
Claudin-2 expression was reported, e.g., in osteoblasts [31], dif-
ferentiated macrophages [28, 30], and endothelial cells of certain
locations [5]. In normal gut, claudin-2 was detected in the intes-
tinal crypts [22] and is overexpressed in inflammatory bowel
disease (IBD) [6], CRC [13], and other tumor types [23].
Recently, claudin family proteins were also detected in
cancer-associated fibroblasts (CAFs) [11]. Functional signifi-
cances of these findings remain to be elucidated. Mechanistic
in vitro studies have indicated effects on differentiation and
migration of claudins in stromal cells [10, 11].
CAFs are the most abundant cells in the solid tumor
stroma. Emerging studies from model systems and from
analyses of clinical samples indicate that CAFs constitute
a diverse set of cells, composed of functionally and clin-
ically relevant subsets, which may regulate tumor initia-
tion, growth, progression, and response to treatment [8,
18]. Concerning the impact of CAFs on drug response,
multiple mechanisms have been suggested which can
broadly be divided into effects on drug exposure/
delivery and effects on drug sensitivity [8, 17].
CAFs, and CAF-derived factors, can control drug delivery
by affecting the interstitial fluid pressure (IFP). Reduction of
IFP by enzymatic ablation of fibroblast-derived hyaluronan
reexpanded the vasculature and improved drug delivery to
the tumor site [21]. Similarly, usage of different PDGFR-β-
antagonists, targeting CAFs, reduced IFP and improved
transcapillary transport and tumoral uptake of chemotherapeu-
tic drugs and radioimmunotherapeutic antibodies [2, 19].
Accordingly, PDGFR inhibitors improved therapeutic effects
of cytotoxic drugs [20].
Based on these earlier findings, this study has explored the
possibility that claudin-2 expression in CAFs is related to
outcome in chemotherapy-treated patients with mCRC.
Materials and methods
A synopsis of the materials and methods is presented here. Full
details are provided in the SupplementaryMaterials andMethods.
The SPCRC cohort—an unselected population diagnosed
with nonresectable mCRC patients during 2003–2006 in three
Scandinavian counties [24]—and the NORDIC-VII cohort
from the randomized study investigated the effects of combin-
ing cetuximab with a regimen of bolus 5-flourouracil (5-FU)/
folinic acid (FA) and oxaliplatin (FLOX) in first-line therapy
of mCRC [27] were used.
Tissue microarrays (TMAs) were made from formalin-
fixed and paraffin-embedded tissue blocks of primary tumor.
For the current study, TMAs from 274 and 262 patients from
the invasive margin and tumor center, respectively, from the
SPCRC cohort and from 315 patients of the NORDIC-VII
cohort were available for immunohistochemistry.
Immunohistochemical staining Single- or double-staining
procedures were applied for the TMA material with the anti-
bodies to claudin-2 (Thermo Fisher Scientific Cat# 32-5600),
CD68 (clone PG-M1; Dako, Inc., Denmark), and pan-
cytokeratin antibody (clone AE1/AE3; Dako, Inc., Denmark).
The abundance of the claudin-2 in tumor cells was evaluated as
an integrated score, considering intensity of the expression and
percentage of positive cells, using a four-graded scale (negative
(0), weak (1), moderate (2), or strong (3)) and then dichoto-
mized for survival analysis. Claudin-2-positive macrophage
score was based on the quantity of marker-positive macro-
phages, irrespective of expression intensity. Claudin-2-
positive CAF score was based on the abundance of dot-like
expression (quantity of dots per area) irrespective of expression
intensity. Evaluation of the ICH was performed by two pathol-
ogists: IH for SPCRC cohort (blinded to clinical and outcome
data of SPCRC cohort) and AM for NORDIC-VII cohort
(blinded to clinical and outcome data of NORDIC-VII).
In situ hybridization procedures RNAscope® 2.5 HD
Reagent Kit-RED (Advanced Cell Diagnostics, Hayward,
CA) and a custom-designed RNAscope probe targeting 489–
1408 of NM_020384.3 were used to detect CLDN2 transcript.
Fibroblast isolation from tumor tissue The tissue samples
were collected from five CRC patients and used to separate
396 Virchows Arch (2018) 472:395–405
fibroblasts. The cells were subjected to immunofluorescence
analysis with antibody to claudin-2 (Thermo Fisher Scientific
Cat# 710221 or Thermo Fisher Scientific Cat# 32-5600), α-
SMA (clone 1A4; Dako, Inc., Denmark, at dilution 1:300), or
E-cadherin ((24E10) rabbit mAb, Cell Signaling Technology,
at dilution 1:300).
Monocyte isolation and differentiation Human monocytes
were isolated from heparinized blood, obtained from healthy
donors (The Republic Research & Production Centre for
Transfusiology and Medical Biotechnologies, Minsk,
Belarus), differentiated intoM0-like cells by adhesion on plas-
tic for 30 min, polarized to M2-like macrophages by incuba-
tion with 2 ng/ml M-CSF (PeproTech, Rocky Hill, NJ, USA)
and/or 40 ng/ml IL-4 (R&D Systems, Minneapolis, MN,
USA) for 6 days and stained with antibodies to claudin-2
(Thermo Fisher Scientific Cat# 710221).
Statistical analyses Cox proportional hazards model was
used to estimate statistical significance and relative hazards
in univariate and multivariate settings. Goodman–Kruskal
gamma test was used for the analyses of marker expression
in different locations. Mann–Whitney U test and ANOVA
tests were used for the analyses of associations between mark-
er expression and clinical characteristics. All statistical tests
were two-sided, and p value < 0.05 was considered statistical-
ly significant. Due to multiple tests applied for the survival
analysis of claudin-2 expression in the SPSS cohort, the
Bonferroni correction for the statistical significance was cal-
culated and p value = 0.005 was considered as the threshold.
All statistical analyses were performed using SPSS V20
(SPSS Inc., Chicago, IL).
Results
Initial analyses were performed on tissue sections from human
CRC tissue to characterize the patterns of claudin-2 expres-
sion. We observed claudin-2 in multiple cell types, including
epithelial cells, endothelial cells, CAFs, and macrophages.
Claudin-2 is expressed in malignant and endothelial cells
In malignant cells, a certain intra- and inter-case variability in
the expression levels of claudin-2 was observed (Fig. 1a).
Furthermore, different patterns of expression were detected
including supra-nuclear, basal, and unpolarized expression
(Supp. Fig. 1A).
To investigate the potential impact on survival of claudin-2
expression pattern in malignant cells, an analysis with survival
data from the SPCRC cohort was performed. Interesting, an
unpolarized pattern was significantly associated with shorter
overall survival (OS) (Supp Fig 2) with median 22.8 months
for unpolarized pattern, and 38.1 and 38.4 months for supra-
nuclear and basal patterns, respectively (p = 0.004). No asso-
ciations with progression-free survival (PFS) were found (data
not shown).
We also observed vascular expression of claudin-2, which
was associated with endothelial cells (Supp. Fig. 1B). The
observation is concordant with earlier reports [25]. A further
analysis of vascular expression of claudin-2 was not per-
formed in this study.
Claudin-2 is expressed in macrophages and CAFs
In agreement with previous studies, the appearance of
claudin-2 in macrophages was also demonstrated by the
presence of claudin-2/CD68 (pan-macrophage marker)
double-positive cells in the stroma (see Fig. 1B and
Supp. Fig. 1C). In noncancerous colonic mucosa, the
claudin-2-positive macrophages represented a fraction
of CD163+ (M2 macrophages) cells with localization
restricted to the subepithelial region (see Supp Fig.2A).
In the tumor stroma, we observed heterogeneous pattern
of claudin-2 expression in macrophages with the pres-
ence of CD68+/cl2−, CD68+/cl2+ (see Fig. 1D2),
CD163+/cl2− and CD163+/cl2+ cells (see Supp
Fig.3B1 and C). Macrophages in peritumoral stroma,
not adjacent to the tumor, were predominantly claudin-
2-negative (see Supp Fig.3B2).
To extend these findings, we investigated the expres-
sion of claudin-2 in human blood monocyte-derived,
polarized M2-class macrophages. M2-macrophage-like
differentiation of human monocyte cells with M-CSF,
IL-4, or M-CSF+IL-4 was reported elsewhere [32] (see
BMaterials and methods^). M0 cells and IL-4-alone or
M-CSF-alone differentiated cells are characterized by
low or absent expression of claudin-2 (see Supp
Fig. 4A–C and 4E). However, when the combination
of M-CSF and IL-4 was used for differentiation, the
macrophages expressed high levels of claudin-2 (see
Supp Fig. 4D, E).
Apart from the claudin-2-positive macrophages and
vessels, additional dispersed dot-like claudin-2 expres-
sion was detected in other cells of the tumor stroma
(Fig. 1C). These cells displayed an elongated spindle-
shaped fibroblast-like morphology and were not juxta-
posed to vessels, suggesting that they were CAFs.
Additional tests were therefore done to validate the
findings from the tissue-based analyses. Cultured prima-
ry fibroblasts, derived from surgically resected human
CRC, were analyzed by IF. Two subsets of fibroblasts
were observed: a subset with low level of cytoplasmic
claudin-2 expression (Fig. 1d, BL^ marked) and a subset
with high level of dot-like claudin-2 expression
(Fig. 1d, BH^ marked). Both cell subsets were positive
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to α-SMA (Fig. 1d). CAF-expression of claudin-2 was
confirmed in another experiment where cocultures of the
primary fibroblasts and the CRC caco-2 cell line re-
vealed claudin-2 expression in the E-cadherin-negative
cells (Supp Fig. 5A.).
In order to validate specificity of the IHC staining of the
claudin-2, we performed both IHC and in situ hybridization
(ISH) on the sequential sections of FFPE sections. The mRNA
targeting probes showed a signal pattern, which was similar to
IHC expression pattern, with positivity in cancer cells, CAFs,
macrophage-like cells, and nonmalignant colon epithelial cells
(Supp Fig. 5B.).
Claudin-2 expression in cancer cells and fibroblasts
at the invasive margin of the tumor is associated
with KRAS mutation status
Following this initial profiling of claudin-2 expression in hu-
man CRC, we focused on the expression of claudin-2 in can-
cer cells and CAFs. As demonstrated by Goodman–Kruskal
gamma test (Supp. Table 1), the expression of claudin-2 in CT
and in IM was concordant based on analyses performed sep-
arately for cancer cells and CAFs (gamma test g = 0.63 and
0.37, respectively, both p < 0.001). When the correlation be-
tween the claudin-2 expression in cancer cells and in CAFs of
a b
c
d
claudin-2
pancytokeratin
b
α-SMAclaudin-2 merge
claudin-2
DAPI
α-SMA
L
H
(A-C):
Fig. 1 Claudin-2 expression in human colorectal cancer tissue. a
Representative image of tumor tissue without (upper image) and with
high (lower image) claudin-2 expression in cancer cells. Note strong
blue staining on pan-cytokeratin (red)-positive areas. b Expression of
the claudin-2 in macrophages. Note dark-blue spots with irregular
shape, frequently with a blank region in the centre (unstained nucleus).
c Dot-like expression of the claudin-2 in cells with fibroblast-like
morphology. d Expression of claudin-2, as determined by IF, in a
fraction of cells within a primary CAF culture (passage 4). Note
claudin-2 dot-like high-level expression in a cell marked BH^ and low-
level diffuse expression in a cell marked BL^ (green) in fraction of CAFs.
Red color used for the visualization of α-SMA
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the same location was analyzed, low concordance was ob-
served in both CT and IM (g = 0.28, p < 0.001, and
g = 0.24, p = 0.001, respectively).
To evaluate associations with clinicopathological charac-
teristics, the semiquantitative data of claudin-2 expression
was dichotomized into high and low values (see BMaterials
and methods^). High claudin-2 in malignant cells at the IM
was more commonly seen in colon than in rectum tumors.
Notably, high claudin-2 expression in malignant cells in the
IM was also associated with KRAS, but not BRAF mutation
status (Table 1.)
CAF-associated claudin-2 status predicts progression-free
survival in the SPCRC cohort
No significant associations were detected between OS and
claudin-2 expression in neither the malignant cells, nor the
CAFs (data not shown). Furthermore, claudin-2 expression
in the malignant cells was not associated with PFS (Supp.
Fig. 6A). However, high expression of claudin-2 in CAFs in
both CTand IM was significantly associated with shorter PFS
(Fig. 2a) with median 8.8 and 7.4 months for low and high
CAF-associated claudin-2 in CT, respectively (p = 0.002), and
10.1 and 7.4 months for low and high CAF-associated
claudin-2 at IM, respectively (p = 0.005).
The univariate analyses were expanded to multivariate
analyses, including performance status, alkaline phosphatase,
BRAF, and KRASmutation status. In these analyses, only the
CAF-associated expression of claudin-2 in the IM acted as an
independent predictor for PFS (Table 2).
CAF-associated expression of claudin-2 at the invasive
margin predicts response to oxaliplatin in the SPCRC
cohorts
The survival analyses described above identified associations
between claudin-2 status in CAFs with PFS, but not with OS.
These findings prompted analyses exploring potential
Table 1 Associations between claudin-2 expression and clinicopathological parameters in patients with mCRC in the SPCRC cohort
Tumor center Invasive margin
Cancer cells Fibroblasts Cancer cells Fibroblasts
n (percent) p value n (percent) p value n (percent) p value n (percent) p value
Low High Low High Low High Low High
Median age
(range)
68 (24–96) 71 (26–92) 0.321* 70 (24–96) 71 (28–92) 0.542* 70 (26–96) 71 (24–92) 0.171* 70 (43–96) 71 (24–92) 0.701*
WHO PS
0 50 (11) 109 (24) 107 (24) 51 (12) 72 (20) 54 (15) 48 (11) 100 (24)
1 38 (9) 97 (22) 0.812 96 (22) 41 (9) 0.461 45 (13) 55 (16) 0.039 51 (12) 79 (19) 0.189
2–4 43 (10) 105 (24) 93 (21) 54 (12) 77 (22) 48 (14) 42 (10) 103 (24)
Alk phosph
Normal 57 (15) 119 (30) 0.430 124 (31) 51 (13) 0.183 72 (23) 62 (20) 0.288 63 (17) 101 (27) 0.139
Elevated 62 (16) 154 (39) 140 (36) 77 (20) 104 (34) 70 (23) 64 (17) 142 (39)
Gender
M 72 (16) 146 (33) 0.124 150 (34) 68 (15) 0.417 103 (29) 70 (20) 0.113 77 (18) 128 (30) 0.074
F 59 (13) 165 (38) 146 (33) 78 (18) 91 (26) 87 (25) 64 (15) 154 (37)
Location
Colon 93 (21) 238 (55) 0.204 218 (50) 114 (26) 0.392 142 (41) 130 (37) 0.035 101 (24) 222 (53) 0.097
Rectum 36 (8) 68 (16) 73 (17) 31 (7) 50 (14) 26 (8) 38 (9) 56 (17)
BRAF
wt 105 (24) 244 (56) 0.399 229 (52) 121 (28) 0.339 148 (43) 122 (36) 0.533 116 (28) 209 (51) 0.052
mut 23 (5) 67 (15) 63 (14) 26 (6) 43 (12) 30 (9) 22 (5) 67 (16)
KRAS
wt 79 (18) 178 (41) 0.316 181 (42) 76 (17) 0.049 124 (37) 72 (21) 0.001 86 (21) 159 (39) 0.250
mut 46 (11) 129 (30) 108 (25) 68 (16) 64 (19) 77 (23) 48 (12) 114 (28)
Chi-square test or Mann–Whitney U test (*) was used for statistical analyses
n number of cases, WHO PSWHO performance status, Alk phosph alkaline phosphatase,M male, F female, mut mutant, wt wild type
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relationships between claudin-2 status and response to treat-
ment. Additional PFS analyses were therefore performed to
identify potential drug-specific associations between CAF-
associated expression of claudin-2 and PFS. Depending on
the treatment regimens used at the first-line treatment, three
groups were identified: 5FU-alone group, 5FU+irinotecan,
and 5FU+oxaliplatin group. The clinical characteristics of
the patients from three treatment groups are shown in Supp.
Table 2. Interestingly, the significant association between
CAF claudin-2 and PFS, as determined by Cox regression
analysis, was only detected in the 5FU+oxaliplatin group (p
value = 0.027 and 0.001 for CT and IM CAF-associated
claudin-2 expression, respectively, Fig. 2b and Supp Fig. 6B).
To expand these findings, multivariable analyses were per-
formed on the treatment-defined subgroups (Table 3). High
CAF-associated claudin-2 expression at IM then acted as a
significant independent marker for shorter PFS in 5-FU+
oxaliplatin group (p = 0.009). The expression in CT was not
statistically significant (data not shown). Similar results were
seen when 5-FU+oxaliplatin group was compared to merged
5FU-alone and 5FU+irinotecan group (data not shown).
These observations indicate that stromal expression of
claudin-2 in the IM in primary CRC tissue predicts the re-
sponse to oxaliplatin in first-line 5-FU-based treatment of
mCRC.
Stromal claudin-2 expression predicts survival also
in the NORDIC-VII cohort of mCRC
Additional analyses were performed to investigate if the find-
ings could be reproduced in an independent patient cohort.
For this purpose, a NORDIC-VII study derived TMA was
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Time (months)
P
r
o
g
r
e
s
s
io
n
 f
r
e
e
 s
u
r
v
iv
a
l
HR=1.52 (95% CI 1.16 – 1.99), p = 0.002
Time (months)
CAF-associated claudin-2 IM
SPCRC cohort
P
r
o
g
r
e
s
s
io
n
 f
r
e
e
 s
u
r
v
iv
a
l
HR=1.50 (95% CI 1.13 – 1.98), p = 0.005
n=274 n=262
CAF-associated claudin-2 CT
5-FU+oxaliplatin
claudin-2 expression:
a
b
120100806040200
1.0
0.8
0.6
0.4
0.2
0.0
120100806040200
1.0
0.8
0.6
0.4
0.2
0.0
p = 0.027
n=162
0.0
1.0
0 3015
CAF-associated claudin-2 IM
5-FU+oxaliplatin
p = 0.001
n=152
0.0
1.0
0 3015
Time (months)
P
r
o
g
r
e
s
s
io
n
 f
r
e
e
 s
u
r
v
iv
a
l
Time (months)
P
r
o
g
r
e
s
s
io
n
 f
r
e
e
 s
u
r
v
iv
a
l
Fig. 2 Associations between claudin-2 and progression-free survival
(PFS). Kaplan–Meier graphs showing associations in the SPCRC
cohort between PFS and claudin-2 expression in stromal cell/CAFs (a).
Results from analyses of 5FU+oxaliplatin subgroup are shown in b.
Results are shown separately for expression in central tumor (CT) (left
panel) or invasive margin (IM) (right panel). HRs from Cox regression
analyses, including confidence intervals, and p values are indicated for all
analyses. Note, according to Bonferrony correction for the statistical
significance, p value = 0.005 shall be considered as the threshold in the
current illustration
400 Virchows Arch (2018) 472:395–405
analyzed with regard to CAF-associated expression of
claudin-2. All patients in the NORDIC-VII trial received com-
bined 5-FU plus oxaliplatin therapy (see BMaterials and
methods^).
In agreement with the findings from the SPCRC cohort, a
statistically significant association between CAF-associated
claudin-2 expression (but not cancer cell-associated claudin-
2 expression) and PFS was detected (Fig. 3a, b).
This analysis provides independent evidence implying
CAF-associated claudin-2 as a marker related to survival in
mCRC treated with 5-FU+oxaliplatin. Notably, the treatment
regimens of the NORDIC-VII population prevented analyses
on oxaliplatin-specific survival associations CAF-associated
claudin-2.
Claudin-2 expression is concordant in primary tumor
and in metastases
The analyses above on survival of mCRC were based on
claudin-2 expression in primary tumors. This prompted anal-
yses where the marker expression in primary tumor and
patient-matched metastases was compared. These analyses
were restricted to the subset of cases where matched primary
tumor and metastatic tissue was available. As shown in Supp.
Table.3, claudin-2 expression showed good concordance be-
tween primary and metastatic tissue in both cancer cells and
CAFs.
Discussion
Claudin-2 overexpression has been observed in CRC tissue.
This is a first study to our knowledge, which reports a cell-
type-specific analysis of the expression pattern of the protein
in CRC.
We confirmed earlier described claudin-2 expression in
cancer cells and described three distinct expression patterns.
The intracellular localization patterns of the claudin-2 were
not associated with the abundance of the protein. Notably, a
survival association was detected for the unpolarized pattern.
Possibly, this finding could be related to cell polarization/
differentiation status of cells, and thus not causally linked to
claudin-2-related biology.
The key findings of the present study are that claudin-2 is
expressed in CAFs in primary tumor tissue of mCRC in a
manner which is linked to KRAS mutation status and
progression-free survival. Notably, the progression-free-
survival association is restricted to the subset of patients treat-
ed with 5-FU+oxaliplatin.
CAF expression of claudin-2 in CRC has not been previ-
ously reported. However, other TJ proteins such as occludin
and claudin-11 have been detected in CAFs of other tumor
types [11]. Preliminary mechanistic studies have linked TJ
protein expression in CAFs to increased migratory activity
[11]. Further mechanistic studies on how claudin-2 expression
affects CRCCAF phenotypes are warranted by the findings of
the present study.
We report an association between oncogenic KRAS status
and claudin-2 expression in malignant cells. Earlier studies
have implied TGF-beta as an inducer of some TJ proteins in
CAFs and epithelial cells [11, 15]. On another hand, some
studies indicate that claudin-2 expression upregulates TGF-
beta production in colonic epithelial cells and induce immune
suppression [1]. Future studies should thus explore if the as-
sociations between oncogenic RAS and CAF-associated
claudin-2 involves RAS-induced TGF-beta production.
The treatment-specific associations between claudin-2 and
outcome are intriguing and merit further investigation.
Experimental studies should explore if claudin-2 status of fi-
broblasts can regulate 5FU/oxaliplatin-sensitivity of
Table 2 Stromal CAF-associated claudin-2 as a prognostic factor for PFS in multivariate analyses in patients with mCRC (SPCRC cohort)
Univariate Multivariate
CT, n = 253 IM, n = 237
Variable HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Stromal claudin-2 CT (high vs. low) 1.52 (1.16–1.99) 0. 002 1.28 (0.96–1.70) 0. 095 – –
Stromal claudin-2 IM (high vs. low) 1.50 (1.13–1.98) 0. 005 – – 1.43 (1.06–1.93) 0.018
Alkaline phosphatase (elevated vs. normal) 1.62 (1.23–2.14) 0.001 1.58 (1.19–2.10) 0.001 1.54 (1.14–2.08) 0.005
Performance status
0 (reference) 1 (ref.) 0.176 1 (ref.) 0.002 1 (ref.) 0.003
(1 vs. 0) 1.22 (0.91–1.63) 0.176 1.20 (0.88–1.62) 0.251 1.27 (0.92–1.75) 0.142
(2–4 vs. 0) 1.39 (0.90–2.13) 0.134 2.08 (1.40–3.11) < 0.001 2.03 (1.35–3.07) 0.001
BRAF (mut vs. wt) 1.65 (1.14–2.38) 0.008 1.73 (1.17–2.55) 0.006 1.63 (1.09–2.46) 0.019
KRAS (mut vs. wt) 1.25 (0.93–1.66) 0.135 1.38 (1.02–1.87) 0.036 1.33 (0.97–1.82) 0.082
CT tumor center, IM invasive margin, HR hazard ratio, CI confidence interval, mut mutant, wt wild type
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cocultured CRC cells. Animal studies can also be performed
where 5FU/oxaliplatin-sensitivity can be analyzed in tumor
xenografts formed after coinjection of CRC cells and CAFs
of defined claudin-2 status.
CAF subsets may have different impact on drug delivery
by affecting the IFP. It has been shown before that increased
fluid flow, caused by the differences between IFP in tumor and
peritumoral regions can affect delivery of molecules in a man-
ner that is related to their molecular weight [3, 16]. Molecular
weights of both fluorouracil and oxaliplatin are comparable
(0.130 and 0.397 kDa, respectively). Possibly, differential as-
sociations with macromolecules could affect delivery of the
drugs and the IFP dependency. Future experimental studies on
this topic are warranted.
Future studies should also consider the possibility
that the oxaliplatin-treated cases represent a subgroup
of CRC where claudin-2 expression is related to intrin-
sic tumor aggressiveness. In the SPCRC cohort, the
oxa l i p l a t i n - r e c e i v i ng g roup d i f f e r s f r om the
fluoropyrimidine-alone-treated group by being younger
and by displaying better WHO PS (Supp. Table 2).
The CAF claudin-2 survival association remained in
analyses performed in age- or PS-defined oxaliplatin-
treated subgroups (data not shown) and in multivariate
Cox regression models. Age or WHO PS is thus not
explaining the treatment-specific CAF claudin-2 associ-
ation with survival. The association seen in the Nordic
VII study, where all patients received oxaliplatin, further
strengthens our conclusion that claudin-2 expression is
related to oxaliplatin treatment response.
Findings of the present study provide additional support for
the notion that CAFs are clinically relevant regulators of drug
sensitivity. As such, findings should stimulate to continued
explorations of CAFs as sources of mechanistically relevant
prognostic and response-predictive biomarkers.
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Fig. 3 Associations between stromal/CAF-associated claudin-2 expression and PFS in the NORDIC-VII cohort. Kaplan–Meier graphs showing
associations in the NORDIC-VII cohort between PFS and claudin-2 expression in cancer cells (a) or in stromal cell/CAFs (b)
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